Showing results (71-80 of 94) with videos related to
Sort By:
Pageof 10
Biomedicines|March 25, 2022
Evaluation of AIF-1 (Allograft Inflammatory Factor-1) as a Biomarker of Crohn's Disease SeverityLuis G Guijarro, David Cano-Martínez, M Val Toledo-Lobo, et al.European Journal of Gastroenterology & Hepatology|April 7, 2020
Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's diseaseMaría Chaparro, Iván Guerra, Marisa Iborra, et al.Gastroenterologia Y Hepatologia|January 13, 2024
Position statement of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis on sexuality and inflammatory bowel diseaseMarta Calvo Moya, Francisco Mesonero Gismero, Cristina Suarez Ferrer, et al.Therapeutic Advances in Gastroenterology|October 11, 2019
Functional rare variants influence the clinical response to anti-TNF therapy in Crohn's diseaseMaría Chaparro, Adrià Aterido, Iván Guerra, et al.Alimentary Pharmacology & Therapeutics|May 3, 2025
Long-Term Outcomes Following Withdrawal of Anti-Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long-Term Study of GETECCUMaría José Casanova, Cristina Rubín de Célix, Sabino Riestra, et al.Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|October 3, 2021
Relationship between IGF-1 and body weight in inflammatory bowel diseases: Cellular and molecular mechanisms involvedLuis G Guijarro, David Cano-Martínez, M Val Toledo-Lobo, et al.Journal of Crohn'S & Colitis|December 5, 2021
Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA RegistryMargalida Calafat, Míriam Mañosa, Elena Ricart, et al.Journal of Crohn'S & Colitis|September 24, 2020
Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA RegistryMaría Chaparro, Ana Garre, Francisco Mesonero, et al.Alimentary Pharmacology & Therapeutics|October 4, 2018
Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registryMaría Chaparro, Ana Garre, Elena Ricart, et al.Postgraduate Medical Journal|June 24, 2024
Influence of familial forms of inflammatory bowel disease on the use of immunosuppressants, biological agents, and surgery in the era of biological therapies. Results from the ENEIDA projectCarlos González-Muñoza, Margalida Calafat, Javier P Gisbert, et al.Pageof 10